Drug Discovery Services by Jubilant Biosys: Advancing Global Healthcare Across
Key Therapeutic Areas
The pharmaceutical industry is constantly evolving, with a strong focus on innovation and efficiency in discovering new therapies. Developing a successful drug requires a deep understanding of biology, chemistry, pharmacology, and translational sciences. At the forefront of this journey is Jubilant Biosys, a global Contract Research, Development, and Manufacturing Organization (CRDMO), delivering end-to-end drug discovery services for leading pharmaceutical and biotech companies.
With proven expertise, cutting-edge infrastructure, and a collaborative approach, Jubilant Biosys accelerates the development of safe and effective drug candidates. The organization specializes in multiple therapeutic areas, including Oncology, Central Nervous System (CNS) disorders, Pain and Inflammation, and Metabolic Disorders, making it a preferred partner in addressing complex healthcare challenges.
Comprehensive Drug Discovery Services at Jubilant Biosys
Jubilant Biosys offers a fullyintegrated drug discovery platform that spans the entire value chain:
• TargetIdentificationandValidation –Understandingdiseasepathways and identifying druggable targets.
• Hit Identification and Lead Generation – High-throughput screening, fragment-based drug design, and computational methods.
• Lead Optimization – Medicinal chemistry and ADME/PK profiling to improve efficacy and safety.
• Preclinical Development – DMPK studies, safety assessment, and process development for clinical readiness.
• Collaborative Research Models – Flexible engagement through FTE (fulltime equivalent) or FFS (fee-for-service) models.
This integrated approach ensures reduced timelines, optimized costs, and enhanced success rates for pharmaceutical partners.
Therapeutic Areas of Expertise
1. Oncology
Cancer continues to be one of the greatest healthcare challenges worldwide. Oncology drug discovery focuses on designing therapies that selectively target cancer cells while minimizing harm to healthy tissues.
Jubilant Biosys contributes to oncology research by:
• Designing small-molecule inhibitors against tumor-specific pathways.
• Utilizing structure-based drug design (SBDD) and fragment-based discovery to accelerate new candidates.
• Conducting high-throughput screening to identify novel leads.
• Optimizing lead compounds for better potency, selectivity, and safety.
The company’s expertise supports the development of targeted therapies, kinase inhibitors, and immuno-oncology agents, helping to advance life-saving cancer treatments.
2. Central Nervous System (CNS) Disorders
Drug discovery for CNS disorders is particularly challenging because of the bloodbrain barrier (BBB) and the complexity of neurological pathways. Jubilant Biosys applies its expertise in medicinal chemistry and DMPK to overcome these barriers.
Key capabilities include:
• Designing BBB-permeable molecules using computational models.
• Optimizing compounds for selectivity, potency, and reduced toxicity.
• Profiling drug candidates for neuropharmacology and behavioral studies.
• Supporting research into disorders such as Alzheimer’s disease,Parkinson’s disease, epilepsy, depression, and multiple sclerosis.
By integrating chemistry, pharmacology, and translational sciences, Jubilant Biosys helps partners advance novel treatments for some of the most difficult-to-treat neurological conditions.
3. Pain and Inflammation
Chronic pain and inflammatory disorders significantly affect quality of life and require therapies that balance efficacy with safety. Jubilant Biosys applies its drug discovery expertise to identify selective molecules that modulate inflammatory pathways.
Services include:
• Hit identification for novel anti-inflammatory and analgesic targets.
• Medicinal chemistry for lead optimization.
• Development of COX inhibitors, JAK inhibitors, and non-opioid analgesics.
• Preclinical validation with pharmacokinetics and safety studies.
These capabilities support the discovery of innovative therapies for arthritis, autoimmune diseases, and neuropathic pain, enabling safer long-term treatments compared to traditional therapies.
4. Metabolic Disorders
Metabolicdiseases,includingdiabetes,obesity,andlipiddisorders,areagrowing global concern. Drug discovery in this area requires precision in targeting complex metabolic pathways and ensuring long-term patient safety.
Jubilant Biosys brings expertise through:
• Designing small molecules that regulate metabolic enzymes and receptors.
• Optimizing oral bioavailability for chronic treatments.
• Synthesizing and scaling promising leads for type 2 diabetes, obesity, and dyslipidemia therapies.
• Conducting DMPK and safety studies to ensure clinical viability.
This integrated support enables pharmaceutical companies to develop nextgeneration treatments that improve quality of life for millions of patients worldwide. Why Choose Jubilant Biosys for Drug Discovery Services?
Partnering with Jubilant Biosys provides significant benefits:
• Global Expertise – Extensive experience across multiple therapeutic areas.
• Integrated Approach – Seamless collaboration between chemistry, biology, pharmacology, and DMPK teams.
• Cutting-Edge Infrastructure – State-of-the-art labs and analytical tools.
• Flexible Business Models – Tailored collaborations through FTE and FFS models.
• Regulatory Compliance – Alignment with global regulatory standards (FDA, EMA, ICH).
These strengths position Jubilant Biosys as a trusted partner for accelerating drug discovery programs.
Conclusion
The success of drug discovery lies in the integration of scientific expertise, innovative platforms, and collaborative partnerships. Jubilant Biosys has establisheditselfas agloballeaderin drugdiscoveryservices,enablingpharmaand biotech companies to bring novel therapies to patients faster.
By focusing on key therapeutic areas such as Oncology, CNS disorders, Pain and Inflammation, and Metabolic Disorders, Jubilant Biosys is addressing critical healthcare challenges with precision-driven solutions. With its world-class infrastructure, skilled scientific teams, and commitment to innovation, Jubilant Biosys continues to advance the future of medicine and global healthcare.
